Diamond Biofund-sponsored Asia-Pacific Biotechnology Investment Forum 12/6 debut Diamond Biofund Chairman William Lu said that after the adoption of the 2007 Biotech New Drug Industry Ordinance, Taiwan has been 10 years ago, which has given Taiwanese biotech industry a However, due to the inability to enter the market, re-clinical trials in hospitals and the non-nuclear pricing of health insurance, the biotech industry in Taiwan is faced with the need to go abroad.

William said that the adoption of the Biotech New Drug Industry Ordinance has indeed enabled Taiwan's biotech industry to thrive. It has also become a region where the development of biotechnology in Asia is quite successful except for Japan. However, in terms of reality, the Taiwanese market accounts for only the world's 0.4%. In particular, the biotech industry is a fairly protected area for all countries. However, it is a pity that Taiwan does not have the final assistance.

William bluntly, Taiwan's annual payment of health insurance billions of hundreds of billions of dollars, if you can afford to pay for these drugs 1%, is the use of domestic biotech industry produced by the drugs, you can make the whole industry live up.

On the contrary, William said Taiwan has trained biotech manufacturers through the biotech new-drug industry regulations. If the manufacturers finally leave, that wasted investment.